Healthcare / Drug Manufacturers - GeneralNasdaqCM
$14.36
-0.13 (-0.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $6.3M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$301M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-8.4%
↓Gross Margin
56.6%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
3.1%
FCF / Net income
-0.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $213.6M · net income $-38.8M · FCF $6.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $213.6M | $213.6M | $228.6M | $306.9M | $369.2M | $583.2M | $614.1M | $429.8M | $229.2M | $181.1M | $130.1M | $81.8M | $54.2M | $26.4M | — | — | — | — |
| Net Income | $-38.8M | $-38.8M | $-82.2M | $-59.1M | $-105.8M | $7.7M | $-18.0M | $-22.6M | $-116.4M | $-67.9M | $-86.3M | $-115.2M | $-56.4M | $-166.2M | $-179.2M | $-69.1M | $-249.6M | $-30.6M |
| EBITDA | $-33.0M | $-33.0M | $-74.2M | $-50.7M | $-100.7M | — | — | — | $-108.2M | $-45.5M | $-65.5M | $-98.1M | $-95.8M | $-181.9M | $-116.6M | $-44.1M | $-45.0M | $-33.5M |
| EPS | -1.80 | -1.80 | -4.00 | -3.00 | -5.20 | 0.40 | -1.00 | -1.40 | -7.80 | -5.00 | -8.20 | -16.60 | -7.20 | -25.60 | -24.80 | -10.60 | — | — |
| Gross Margin | 56.6% | 56.6% | 35.6% | 53.9% | 65.7% | 79.2% | 78.6% | 77.7% | 76.2% | 75.2% | 73.6% | 65.9% | 62.2% | 54.8% | — | — | — | — |
| Operating Margin | -6.5% | -6.5% | -40.2% | -18.4% | -25.0% | 1.8% | -3.2% | -5.6% | -47.2% | -25.2% | -50.4% | -120.1% | -177.0% | -691.1% | — | — | — | — |
| Net Margin | -18.2% | -18.2% | -35.9% | -19.3% | -28.7% | 1.3% | -2.9% | -5.3% | -50.8% | -37.5% | -66.4% | -140.9% | -104.0% | -630.8% | — | — | — | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | — | — | 0.08 | 0.30 | -1.09 | -9.40 | -0.71 | -1.01 | -2.59 | -21.30 | — | — | — |
| Current Ratio | 3.48 | 3.48 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $6.7M | $6.7M | $-31.0M | $6.3M | $-180.7M | — | $-22.0M | $-11.8M | $-94.8M | $-32.8M | $-71.8M | — | — | $-190.3M | $-122.9M | $-39.8M | $-33.9M | $-28.5M |
| Returns | ||||||||||||||||||
| ROE | -8.4% | -8.4% | -16.9% | -10.7% | -17.8% | 1.2% | -2.9% | -3.7% | -76.4% | 104.2% | 953.3% | 89.2% | 63.7% | 491.0% | 4483.0% | 1159.4% | 123.3% | -463.9% |
| Valuation | ||||||||||||||||||
| P/B | 0.65 | 0.65 | 0.45 | 0.64 | 0.97 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -6.5% | -6.5% | -25.5% | -16.9% | — | -5.0% | 42.9% | 87.5% | 26.6% | 39.2% | 59.1% | 50.8% | 105.7% | — | — | — | — | — |
| EPS Growth | 55.0% | 55.0% | -33.3% | 42.3% | — | 140.0% | 28.6% | 82.1% | -56.0% | 39.0% | 50.6% | -130.6% | 71.9% | -3.2% | -134.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+23.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.00 → -1.80
Residual
+23.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.